5 recruiting, 4 completed, 4 unknown, 1 active not recruiting. 4 Phase 3, 3 Phase 2, 1 Early Phase 1, 1 Not applicable, 1 Phase 1.
Follow Antisynthetase syndrome: new trials by email Literature Review of Antisynthetase syndrome trials Research Report on Antisynthetase syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome JAK Inhibitor, Calcineurin Inhibitors (CNI) - Antisynthetase Syndrome, Interstitial Lung Disease (ILD) | Not applicable | Recruiting | China-Japan Friendship Hospital | 80 | 2026-05-18 | 2026-06-03 |
| Descartes-08 in Autoantibody Myositis Descartes-08, Placebo - Antisynthetase Syndrome | Phase 2 | Recruiting | Cartesian Therapeutics | 60 | 2026-04-28 | 2026-08-17 |
| An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis anti CD19 CAR NK cells - Antisynthetase Syndrome, Rheumatoid Arthritis | Early Phase 1 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 24 | 2025-05-20 | 2025-04-30 |
| BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T - Inflammatory Myopathy | Phase 1 | Recruiting | iCell Gene Therapeutics | 10 | 2025-03-20 | 2026-07-20 |
| Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung Disease BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT - Antisynthetase Syndrome | Unknown | Central Hospital, Nancy, France | 24 | 2024-08-26 | 2024-08-27 | |
| Evaluation of Circulating Neutrophils in Antisynthetase Syndrome circulating neutrophils - Antisynthetase Syndrome | Completed | Central Hospital, Nancy, France | 89 | 2024-01-01 | 2026-04-20 | |
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy Efgartigimod PH20 SC - Myositis, Active Idiopathic Inflammatory Myopathy | Phase 3 | Enrolling by invitation | argenx | 240 | 2023-09-12 | 2026-10-16 |
| Evaluation of Peripheral Neutrophils in Antisynthetase Syndrome Antisynthetase Syndrome | Completed | Central Hospital, Nancy, France | 40 | 2023-02-01 | 2023-08-03 | |
| A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. EFG PH20 SC, PBO - Active Idiopathic Inflammatory Myopathy, Myositis | Phase 2 / Phase 3 | Completed | argenx | 265 | 2022-10-12 | 2026-09-21 |
| Tocilizumab in Refractory ASS-ILD Tociliuzumab - Antisynthetase Syndrome, Tocilizumab | Completed | Hu Yinan | 111 | 2022-01-01 | 2026-06-23 | |
| Add-on Intravenous Immunoglobulins in Early Myositis Immune Globulin Intravenous (Human), Placebo - Inflammatory Myopathy, Idiopathic, Dermatomyositis | Phase 2 / Phase 3 | Active not recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 44 | 2021-09-13 | 2026-02-27 |
| Evaluation of Interstitial Lung Disease Severity in Patients With Antisynthetase Syndrome According to Specific Autoantibodies Profile Follow-up - Antisynthetase Syndrome | Unknown | Central Hospital, Nancy, France | 200 | 2021-06-01 | 2021-06-14 | |
| Association Between Cancer and Anti-synthetase Syndrome Antisynthetase Syndrome | Unknown | Central Hospital, Nancy, France | 200 | 2021-04-01 | 2021-06-28 | |
| Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease Cyclophosphamide and azathioprine, Tacrolimus - Antisynthetase Syndrome (ASS), Interstitial Lung Disease | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 76 | 2021-02-05 | 2021-02-09 |
| Optimizing Treatment on Idiopathic Inflammatory Myopathies Intravenous Infusion - Idiopathic Inflammatory Myopathies | Recruiting | University of Sao Paulo | 60 | 2005-01-01 | 2024-12-05 |
Myositis (7) · Dermatomyositis (5) · Polymyositis (5) · Lung Diseases, Interstitial (3) · Arthritis, Rheumatoid (1) · Neoplasms (1)
Musculoskeletal Diseases (8) · Muscular Diseases (7) · Nervous System Diseases (7) · Neuromuscular Diseases (7) · Connective Tissue Diseases (6) · Skin and Connective Tissue Diseases (6) · Skin Diseases (5) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Arthritis (1) · Autoimmune Diseases (1) · Immune System Diseases (1) · Joint Diseases (1) · Rheumatic Diseases (1)
Azathioprine (1) · Calcineurin Inhibitors (1) · Cyclophosphamide (1) · Dosage Forms (1) · Immunoglobulins, Intravenous (1) · Infusions, Intravenous (1) · Janus Kinase Inhibitors (1) · Sodium Chloride (1) · Tacrolimus (1) · tocilizumab (1)
Central Hospital, Nancy, France (5) · argenx (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Assistance Publique - Hôpitaux de Paris (1) · Cartesian Therapeutics (1) · China-Japan Friendship Hospital (1) · Hu Yinan (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University of Sao Paulo (1) · iCell Gene Therapeutics (1)
France (7) · China (6) · Netherlands (3) · United States (3) · Argentina (2) · Austria (2) · Belgium (2) · Bulgaria (2) · Cyprus (2) · Czechia (2) · Denmark (2) · Georgia (2) · Germany (2) · Greece (2) · Ireland (2)
Paul Decker, MD (2) · Samuel K Shinjo, PhD (1) · Thomas Moulinet, MD (1)
2016 (1)